Skip to main content
. 2020 Apr 28;11(17):1478–1492. doi: 10.18632/oncotarget.27539

Figure 7. Suppression of mTOR signaling in breast cancer patients treated with abemaciclib.

Figure 7

GSEA enrichment plot for mTOR signature following two weeks of abemaciclib monotherapy treatment (early vs baseline) in the neoMONARCH clinical trial. Nominal p < 0.01, FDR q < 0.01. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.